PLEXUS RECEIVES FDA APPROVAL FOR ASIAN MANUFACTURING FACILITY

NEENAH, WI, September 27, 2007 – Plexus Corp. (NASDAQ: PLXS), a contract manufacturer of electronics products, today announced that one of its Penang, Malaysia facilities has received approval from the Food and Drug Administration (FDA), through its premarket approval (PMA) supplement evaluation process, to manufacture class III finished devices on behalf of a large tier- one medical OEM. This approval comes following an extensive on-site audit in Penang by the FDA.

Dean Foate, Chief Executive Officer of Plexus, commented, “This approval is another significant milestone in our more than 20 year history of supporting the increasingly global outsourcing requirements of medical device OEMs. Plexus has three FDA registered manufacturing facilities in the US, Mexico and Malaysia, two of which are now approved to manufacture finished class III medical devices. Additionally, four of our engineering facilities and six of our manufacturing facilities are also ISO 13485:2003 registered. With approximately a quarter of our annual revenues coming from product design, supply chain management and manufacturing services for medical device OEMs, Plexus is a leading contract manufacturer for the medical device industry.”

Andy Hyatt, Vice President of Plexus’ Medical Sector, added, “We believe Plexus is one of the first contract manufacturers to have an Asian facility with FDA approval to manufacture finished class III medical devices. We understand how competitive the medical device market is, and are committed to developing scalable, global solutions that will create a competitive advantage for our customers in their end markets. We will continue to broaden our global service offering and expect to be registering additional facilities in Malaysia and the UK with the FDA over the coming year.”

For further information, please contact:

Kristian Talvitie, Vice President – Marketing, Branding and Communications

920-969-6160 or kristian.talvitie@plexus.com

About Plexus Corp. – The Product Realization Company

Plexus ( www.plexus.com ) is an award-winning participant in the Electronics Manufacturing Services (EMS) industry, providing product design, test, manufacturing, fulfillment and aftermarket solutions to branded product companies in the Wireline/Networking, Wireless Infrastructure, Medical, Industrial/Commercial and Defense/Security/Aerospace industries.

The Company’s unique Focused Factory manufacturing model and global supply chain solutions are strategically enhanced by value-added product design and engineering services. Plexus specializes in customer programs that require flexibility, scalability, technology and quality. Plexus provides award-winning customer service to more than 100 branded product companies in North America, Europe and Asia.

Safe Harbor and Fair Disclosure Statement

The statements contained in this release which are guidance or which are not historical facts (such as statements in the future tense and statements including “believe,” “expect,” “intend,” “anticipate,” “target” and similar terms and concepts), including all discussions of periods which are not yet completed, are forward-looking statements that involve risks and uncertainties. Particular risks include, among other things, the readiness of our facilities or our customers to seek approval from the FDA to manufacture medical devices, and the timing of any approval from the FDA for certain manufacturing facilities. All Plexus operations are subject to other risks, including, but not limited to: the economic performance of the electronics, technology and defense industries; the risk of customer delays, changes or cancellations in both ongoing and new programs; the poor visibility of future orders in the defense industry; the Company’s ability to secure new customers and maintain its current customer base; the risks of concentration of work for certain customers; material cost fluctuations and the adequate availability of components and related parts for production; the effect of changes in average selling prices; the effect of start-up costs of new programs and facilities, including our planned expansions in Asia; the adequacy of restructuring and similar charges as compared to actual expenses; the degree of success and the costs of efforts to improve the financial performance of its Mexican operations; possible unexpected costs and operating disruption in transitioning programs; the costs and inherent uncertainties of pending litigation; the effect of general economic conditions and world events (such as terrorism and war in the Middle East); the impact of increased competition; and other risks detailed in the Company’s Securities and Exchange Commission filings.

# # #